These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37642224)

  • 1. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
    Matsuda K; Nagai S; Sugimoto K
    Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaceutical approval process of drugs for hematological malignancies: current situations in Japan].
    Nagai S
    Rinsho Ketsueki; 2020; 61(5):437-444. PubMed ID: 32507805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delays in neurological drug development in Japan.
    Shimazawa R; Ikeda M
    Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
    Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
    Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delays in psychiatric drug development in Japan.
    Shimazawa R; Kusumi I; Ikeda M
    J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncology drug lag in Japan: has it improved over the last decade?
    Tachibana Y; Narukawa M
    Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
    Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
    Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.